VYNE
VYNE Therapeutics Inc.0.4027
+0.0427+11.9%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
13.40MP/E (TTM)
-Basic EPS (TTM)
-0.79Dividend Yield
0%Recent Filings
8-K
Nasdaq grants VYNE extension
10-K
FY2025 results
VYNE Therapeutics posted FY2025 net loss of $26.5M, improved from $39.8M in FY2024, as R&D expenses dropped 38% to $19.2M after terminating repibresib gel's Phase 2b vitiligo trial (missed F-VASI50 endpoint) and VYN202's Phase 1b psoriasis study amid FDA partial clinical hold. Q4 saw sharp sequential R&D cuts while pursuing strategic review, culminating in December's merger agreement with Yarrow—expected Q2 2026 close with $200M Yarrow financing, $15M special dividend to pre-merger VYNE holders, and VYNE shareholders diluted to ~3%. Cash fell to $29.0M from $66.9M, runway through merger close. Merger failure risks dissolution.
8-K
VYNE amends Yarrow merger
VYNE Therapeutics amended its December 17, 2025 merger agreement with Yarrow Bioscience on January 30, 2026, allowing pre-funded warrants for Yarrow holders exceeding beneficial ownership limits up to 19.99%. It also extends the Parent Pre-Closing Dividend to cover shares underlying Parent Warrants. Warrants keep economics intact. Filing precedes S-4.
8-K
VYNE merges with Yarrow
VYNE Therapeutics signed a merger agreement on December 17, 2025, with Yarrow Bioscience, where a merger sub merges into Yarrow, leaving it as VYNE's wholly-owned subsidiary. Pre-merger Yarrow investors secured $200M in financings; post-merger, Yarrow holders own ~97%, VYNE ~3%. VYNE plans a $14.5-16.5M pre-closing dividend to its stockholders. Closing eyed for Q2 2026, pending approvals. Stockholder votes required.
8-K
Annual meeting results disclosed
VYNE Therapeutics held its 2025 annual meeting on December 12, with 50.1% of shares present. Stockholders elected Elisabeth Sandoval Little and Steven Basta as Class I directors despite significant withheld votes; ratified Baker Tilly US, LLP as auditors; and advisory approved executive compensation. Directors now serve until 2028. Quorum barely met.
BRNS
Barinthus Biotherapeutics plc
0.74-0.00
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
DYN
Dyne Therapeutics, Inc.
19.55-0.04
FBIO
Fortress Biotech, Inc.
3.51+0.19
IMA
ImageneBio, Inc.
6.25+0.08
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
NKTR
Nektar Therapeutics
49.16-4.14
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
THAR
Tharimmune, Inc.
2.41+0.01